Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)

Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion

(2019) Andre Lamy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

(2019) Deepak L Bhatt et al.   LANCET

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

(2019) Roxana Mehran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor in Patients with Stable Coronary Disease and Diabetes

(2019) P. Gabriel Steg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

(2018) Stuart J Connolly et al.   LANCET

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

(2017) John W. Eikelboom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

(2015) Robert W. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

(2015) Marc P. Bonaca et al.   NEW ENGLAND JOURNAL OF MEDICINE

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents

(2014) Laura Mauri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

(2011) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis

(2008) Anthony A Bavry et al.   LANCET

Clinical in-stent restenosis with bare metal stents: Is it truly a benign phenomenon?

(2007) Kevin R. Bainey et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY